Synopsys to Report Q2 Earnings: What's in Store for the Stock?

26.05.25 15:16 Uhr

Werte in diesem Artikel
Aktien

76,00 EUR 0,50 EUR 0,66%

450,40 EUR 7,00 EUR 1,58%

Indizes

21.415,0 PKT 499,3 PKT 2,39%

19.199,2 PKT 462,0 PKT 2,47%

5.921,5 PKT 118,7 PKT 2,05%

Synopsys SNPS is scheduled to report second-quarter fiscal 2025 results on May 28, after market close.Synopsys expects non-GAAP earnings per share between $3.37 and $3.42. The Zacks Consensus Estimate for fiscal second-quarter earnings is pinned at $3.39 per share, which indicates an increase of 13% year over year. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).The company anticipates revenues between $1.585 billion and $1.615 billion for the fiscal second quarter. The Zacks Consensus Estimate is pegged at $1.60 billion, which suggests an increase of 10.10% from the year-ago period's reported figure.In the trailing four quarters, SNPS’ earnings surpassed the Zacks Consensus Estimate thrice while missing the same on one occasion, with an average surprise of 3.69%. Synopsys, Inc. Price and EPS Surprise Synopsys, Inc. price-eps-surprise | Synopsys, Inc. QuoteFactors Influencing Synopsys’ Q2 ResultsSynopsys’ fiscal second-quarter performance is likely to have benefited from robust demand in the AI and high-performance computing end markets. Strong momentum around Synopsys’ newly expanded hardware-assisted verification (HAV) portfolio is expected to have boosted top-line growth during the quarter to be reported. The launch of next-generation HAPS 200 prototyping systems and ZeBu 200 emulation systems, delivering up to 2x better performance compared to prior versions, has strengthened Synopsys’ leadership in HAV. Major customers, including AMD, ARM, NVIDIA and SiFive, have begun deploying these technologies, are likely to have contributed positively in the to-be-reported quarter.The company’s advancement in agent AI is anticipated to have further supported second-quarter performance. By enabling engineers to task autonomous agents with executing complex workflows, Synopsys expects to unlock massive productivity gains across the industry. The continued adoption of Synopsys.ai across design implementation, verification, test, and analog tools is expected to have driven meaningful growth. Synopsys’ IP development for the global foundry ecosystem is also expected to contribute positively to the to-be-reported quarter results. Silicon success for PCIe 4.05 IP on Samsung’s SF8 process, targeting automotive, mobile, networking, and storage applications, as well as successful deployment of one-time programmable non-volatile memory IP on TSMC’s N4, N5, N6, and N7 nodes, is likely to have supported demand, particularly in security and encryption-related solutions.However, tightening budgets among corporations due to ongoing macroeconomic challenges and unfavorable currency exchange rates are expected to have partially offset the positive impacts of the growth drivers.What Our Model Says About SNPSOur proven model does not conclusively predict an earnings beat for SNPS this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. However, that’s not the case here.Though SNPS currently carries a Zacks Rank #3, it has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Stocks With Favorable CombinationDell Technologies DELL, Nutanix NTNX and Salesforce CRM are some stocks that have a favorable combination.Dell Technologies has an Earnings ESP of +1.46% and a Zacks Rank #3 at present. DELL shares have lost 2.7% year to date. DELL is set to report its first-quarter fiscal 2026 results on May 29. You can see the complete list of today’s Zacks #1 Rank stocks here.Nutanix has an Earnings ESP of +5.26% and a Zacks Rank #3 at present. NTNX shares have gained 30.3% year to date. NTNX is slated to report the third quarter of fiscal 2025 results on May 28.Salesforce has an Earnings ESP of +0.76% and a Zacks Rank #3 at present. CRM shares have plunged 18.3% year to date. CRM is slated to report its first-quarter fiscal 2026 results on May 28. 7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.0% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Salesforce Inc. (CRM): Free Stock Analysis Report Dell Technologies Inc. (DELL): Free Stock Analysis Report Synopsys, Inc. (SNPS): Free Stock Analysis Report Nutanix (NTNX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Q2 und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Q2

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Q2

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Synopsys Inc.

Wer­bung

Analysen zu Synopsys Inc.

DatumRatingAnalyst
22.08.2019Synopsys BuyNeedham & Company, LLC
03.04.2019Synopsys BuyNeedham & Company, LLC
28.03.2019Synopsys BuyNeedham & Company, LLC
06.12.2018Synopsys BuyNeedham & Company, LLC
06.12.2018Synopsys BuyThe Benchmark Company
DatumRatingAnalyst
22.08.2019Synopsys BuyNeedham & Company, LLC
03.04.2019Synopsys BuyNeedham & Company, LLC
28.03.2019Synopsys BuyNeedham & Company, LLC
06.12.2018Synopsys BuyNeedham & Company, LLC
06.12.2018Synopsys BuyThe Benchmark Company
DatumRatingAnalyst
09.09.2015Synopsys HoldThe Benchmark Company
04.12.2008Synopsys UpgradeCitigroup Corp.
02.02.2007Synopsys neutralDA Davidson
31.01.2007Update Synopsys Inc.: NeutralDA Davidson
30.11.2006Synopsys holdDeutsche Securities
DatumRatingAnalyst
21.08.2008Synopsys DowngradeCitigroup Corp.
24.06.2005Synopsys underweightPrudential Financial

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Synopsys Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen